Literature DB >> 14987553

Vascular endothelial growth factor-C: a growth factor for lymphatic and blood vascular endothelial cells.

B Enholm1, L Jussila, M Karkkainen, K Alitalo.   

Abstract

The endothelial cells lining all vessels of the circulatory system have been recognized as key players in a variety of physiological and pathological settings. They act as regulators of vascular tone via the inducible nitric oxide system and in angiogenesis, the formation of blood vessels de novo. Aberrant regulation of endothelial cells contributes to tumor formation, atherosclerosis, and diseases such as psoriasis and rheumatoid arthritis. Among the most recently discovered growth factors for endothelial cells are newly isolated members of the platelet-derived growth factor/vascular endothelial growth factor (VEGF) family, VEGF-B, VEGF-C, and VEGF-D. VEGF-C is the ligand for the receptor tyrosine kinase VEGFR-3 (also known as Flt4), which is expressed predominantly in lymphatic endothelium of adult tissues, but a proteolytically processed form of VEGF-C can also activate VEGFR-2 of blood vessels. The lymphatic vessels have been known since the 17th century, but their specific roles in health and disease are still poorly understood. With the discovery of VEGF-C and its cognate receptor VEGFR-3, the regulation and functions of this important component of the circulatory system can be investigated.

Entities:  

Year:  1998        PMID: 14987553     DOI: 10.1016/s1050-1738(98)00026-7

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  7 in total

1.  Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells.

Authors:  Shunsuke Fukumoto; Masayo Morifuji; Yoshinori Katakura; Masamichi Ohishi; Seiji Nakamura
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

2.  A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3'-kinase activation and endothelial cell migration.

Authors:  H Gille; J Kowalski; L Yu; H Chen; M T Pisabarro; T Davis-Smyth; N Ferrara
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

3.  Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2.

Authors:  Roni Mamluk; Irvith M Carvajal; Brent A Morse; Henry Wong; Janette Abramowitz; Sharon Aslanian; Ai-Ching Lim; Jochem Gokemeijer; Michael J Storek; Joonsoo Lee; Michael Gosselin; Martin C Wright; Ray T Camphausen; Jack Wang; Yan Chen; Kathy Miller; Kerry Sanders; Sarah Short; Jeff Sperinde; Gargi Prasad; Stephen Williams; Robert Kerbel; John Ebos; Anthony Mutsaers; John D Mendlein; Alan S Harris; Eric S Furfine
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

4.  Transcriptional program induced by factor VIIa-tissue factor, PAR1 and PAR2 in MDA-MB-231 cells.

Authors:  T Albrektsen; B B Sørensen; G M Hjortø; J Fleckner; L V M Rao; L C Petersen
Journal:  J Thromb Haemost       Date:  2007-04-27       Impact factor: 5.824

5.  Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer.

Authors:  Tian-Bao Wang; Mei-Hai Deng; Wan-Shou Qiu; Wen-Guang Dong
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

6.  Type 1 IFN and PD-L1 Coordinate Lymphatic Endothelial Cell Expansion and Contraction during an Inflammatory Immune Response.

Authors:  Erin D Lucas; Jeffrey M Finlon; Matthew A Burchill; Mary K McCarthy; Thomas E Morrison; Tonya M Colpitts; Beth A Jirón Tamburini
Journal:  J Immunol       Date:  2018-07-25       Impact factor: 5.422

Review 7.  The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway.

Authors:  Tara Karnezis; Ramin Shayan; Stephen Fox; Marc G Achen; Steven A Stacker
Journal:  Oncotarget       Date:  2012-08-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.